Phil F. Cheng

5.2k citations

96 papers · 2.9k indexed · h-index 29

Oncology top 2%
- Cancer Immunotherapy and Biomarkers 21
- Cutaneous Melanoma Detection and Management 18
- CAR-T cell therapy research 17
- Cancer Cells and Metastasis 6
Immunology top 5%
- Immunotherapy and Immune Responses 17
Cancer Research top 5%
- Cancer Genomics and Diagnostics 6
Molecular Biology top 5%
- Melanoma and MAPK Pathways 38
- Epigenetics and DNA Methylation 6
Dermatology top 2%

Co-authors: Mitchell P. Levesque Reinhard Dummer Lukas Sommer Daniel Widmer Ossia M. Eichhoff Marieke I.G. Raaijmakers Daniel Zingg Raffaella Santoro
Cited by: Oncology Immunology Cancer Research
Journals: Journal of Clinical Investigation (1 paper)Nature Communications (4 papers)Journal of Clinical Oncology (1 paper)
Partner nations: Switzerland United States Germany

In The Last Decade

Phil F. Cheng

93 papers receiving 2.9k citations

Peers

Countries citing papers authored by Phil F. Cheng

Since Specialization

Citations

This map shows the geographic impact of Phil F. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phil F. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phil F. Cheng more than expected).

Fields of papers citing papers by Phil F. Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phil F. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phil F. Cheng. The network helps show where Phil F. Cheng may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Phil F. Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Phil F. Cheng Line = papers co-authored together Phil F. Cheng links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Uncovering the Distinct Role of Phleum p 4 in Grass Pollen Allergy: Sensitization Patterns in 1963 Swiss Patients International Journal of Molecular Sciences ·Patrick Frey,Phil F. Cheng,Peter Schmid‐Grendelmeier,Carole Guillet	2025	1
2	Human Dermal Microvascular Arterial and Venous Blood Endothelial Cells and Their Use in Bioengineered Dermo‐Epidermal Skin Substitutes Small Methods ·Dominic Rütsche,Monica Nanni,Phil F. Cheng,Nicolà Caflisch,Aizhan Tastanova,C Jenni,Mitchell P. Levesque,Ueli Moehrlen,Agnes S. Klar,Thomas Biedermann	2025	1
3	Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening? European Journal of Cancer ·Sara E. Cerminara,Phil F. Cheng,Lisa Kostner,Stéphanie Huber,Michael Kunz,Julia‐Tatjana Maul,Jette S. Böhm,Chiara F. Dettwiler,Anna Geser,Cécile Jakopović,Livia M. Stoffel,Jelissa Katharina Peter,Mitchell P. Levesque,Alexander A. Navarini,Lara Valeska Maul	2023	32
4	Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma Cancer Research ·Lorenza P. Ferretti,Flurina Böhi,Deena M. Leslie Pedrioli,Phil F. Cheng,E Ferrari,Petra Baumgaertner,Abdiel Alvarado-Diaz,Federica Sella,Alessandra Cereghetti,Patrick Turko,Roni H. G. Wright,Katrien De Bock,Daniel E. Speiser,Roberto Ferrari,Mitchell P. Levesque,Michael O. Hottiger	2023	11
5	Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors Cancer Medicine ·Esmée L. Looman,Phil F. Cheng,Julia Lai‐Kwon,Liza Morgan,Marlies Wakkee,Reinhard Dummer,Florentia Dimitriou	2023	5
6	Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis Pharmaceuticals ·Lukas Kraehenbuehl,Stephanie Schneider,Laura Pawlik,Joanna Mangana,Phil F. Cheng,Reinhard Dummer,Barbara Meier	2023	0
7	Mycobacterial infection aggravates Helicobacter pylori-induced gastric preneoplastic pathology by redirection of de novo induced Treg cells Cell Reports ·Mariela Artola-Borán,Angela Fallegger,Martina Priola,Rima Jeske,Tim Waterboer,Anders B. Dohlman,Xiling Shen,Sebastian Wild,Jiazhuo He,Mitchell P. Levesque,Shída Yousefi,Hans‐Uwe Simon,Phil F. Cheng,Anne Müller	2022	6
8	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis Cancers ·Florentia Dimitriou,Ramon Staeger,Melike Ak,Matias Maissen,Ken Kudura,Marjam J. Barysch,Mitchell P. Levesque,Phil F. Cheng,Reinhard Dummer,Joanna Mangana	2021	21
9	A Comparative Study of Real-Time RT-PCR–Based SARS-CoV-2 Detection Methods and Its Application to Human-Derived and Surface Swabbed Material Journal of Molecular Diagnostics ·Aizhan Tastanova,Corinne I. Stoffel,Andreas Dzung,Phil F. Cheng,Elisa Bellini,Pål Johansen,Agathe Duda,Stephan Nobbe,Reto Lienhard,Philipp P. Bosshard,Mitchell P. Levesque	2021	24
10	Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma Non-Coding RNA ·Marina Tusup,Phil F. Cheng,Ernesto Picardi,Austeja Raziunaite,Reinhard Dummer,Mitchell P. Levesque,Lars E. French,Emmanuella Guenova,Thomas M. Kündig,Steve Pascolo	2021	3
11	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases European Journal of Cancer ·Marie-Luise Hilbers,Florentia Dimitriou,Peter K. H. Lau,Prachi Bhave,Grant A. McArthur,Lisa Zimmer,Ken Kudura,Camille L. Gérard,Mitchell P. Levesque,Olivier Michielin,Reinhard Dummer,Phil F. Cheng,Joanna Mangana	2021	11
12	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition Journal of Investigative Dermatology ·Mai Q. Nguyen,Jessica L.F. Teh,Timothy J. Purwin,Inna Chervoneva,Michael A. Davies,Katherine L. Nathanson,Phil F. Cheng,Mitchell P. Levesque,Reinhard Dummer,Andrew E. Aplin	2020	28
13	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors Cancer Immunology Research ·Jessica L.F. Teh,Dan A. Erkes,Phil F. Cheng,Manoela Tiago,Nicole A. Wilski,Conroy O. Field,Inna Chervoneva,Mitch P. Levesque,Xiaowei Xu,Reinhard Dummer,Andrew E. Aplin	2020	13
14	SMAD signaling promotes melanoma metastasis independently of phenotype switching Journal of Clinical Investigation ·Eylül Tuncer,Raquel R. Calçada,Daniel Zingg,Sandra Varum,Phil F. Cheng,Sandra N. Freiberger,Chu‐Xia Deng,Ingo Kleiter,Mitchell P. Levesque,Reinhard Dummer,Lukas Sommer	2019	37
15	Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma Journal of Investigative Dermatology ·Judith Wenzina,Silvio Holzner,Emmi Puujalka,Phil F. Cheng,Agnes Forsthuber,Karin Neumüller,Klaudia Schossleitner,Beate M. Lichtenberger,Mitchell P. Levesque,Peter Petzelbauer	2019	11
16	In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms Cancer Discovery ·Jessica L.F. Teh,Phil F. Cheng,Timothy J. Purwin,Neda Nikbakht,Prem Patel,Inna Chervoneva,Adam Ertel,Paolo Fortina,Ines Kleiber,Kim HooKim,Michael A. Davies,Lawrence N. Kwong,Mitch P. Levesque,Reinhard Dummer,Andrew E. Aplin	2018	61
17	CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17–Mediated Psoriasiform Skin Inflammation In Vivo Journal of Investigative Dermatology ·Mark Mellett,Barbara Meier,Deepa Mohanan,Rebekka Schairer,Phil F. Cheng,Takashi Satoh,Betina Kiefer,Caroline Ospelt,Stephan Nobbe,Margot Thome,Emmanuel Contassot,Lars E. French	2018	69
18	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma Cancer Immunology Research ·Sabrina A. Hogan,Anaïs Courtier,Phil F. Cheng,Nicoletta F. Jaberg-Bentele,Simone M. Goldinger,Manuarii Manuel,Solène Perez,Nadia Plantier,Jean-François Mouret,Thi Dan Linh Nguyen‐Kim,Marieke I.G. Raaijmakers,Pia Kvistborg,Nicolas Pasqual,John B.A.G. Haanen,Reinhard Dummer,Mitchell P. Levesque	2018	100
19	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma Cancer Research ·Karīna Siliņa,Alex Soltermann,Farkhondeh Movahedian Attar,Ruben Casanova,Zina M. Uckeley,Helen Thut,Muriel Wandres,Sergejs Isajevs,Phil F. Cheng,Alessandra Curioni‐Fontecedro,Periklis Foukas,Mitchell P. Levesque,Holger Moch,Aija Linē,Maries van den Broek	2017	297
20	Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2 Molecular Cancer Therapeutics ·Sandra N. Freiberger,Phil F. Cheng,Guergana Iotzova-Weiss,Johannes Neu,Qinxiu Liu,Piotr Dziunycz,John R. Zibert,Reinhard Dummer,Kresten Skak,Mitchell P. Levesque,Günther F.L. Hofbauer	2015	35

About Phil F. Cheng

Phil F. Cheng is a scholar working on Oncology, Dermatology and Immunology, having authored 96 papers that have together received 2.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (38 papers), Cancer Immunotherapy and Biomarkers (21 papers), Cutaneous Melanoma Detection and Management (18 papers), Immunotherapy and Immune Responses (17 papers), CAR-T cell therapy research (17 papers), Cancer Cells and Metastasis (6 papers), Cancer Genomics and Diagnostics (6 papers) and Epigenetics and DNA Methylation (6 papers). The work is most often cited by research in Oncology (1.3k citations), Immunology (827 citations) and Cancer Research (433 citations). Phil F. Cheng has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Mitchell P. Levesque, Reinhard Dummer, Lukas Sommer, Daniel Widmer, Ossia M. Eichhoff, Marieke I.G. Raaijmakers, Daniel Zingg, Raffaella Santoro, Keith S. Hoek and Holger Moch. Their work appears in journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact